Collagenase Gel Formulation for Controlled Enzyme Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases involving collagen alterations, such as Dupuytren's contracture, using a 1:1 ratio of Collagenase G and H, face challenges including difficulty in activity control, secondary effects like tendon rupture, allergic reactions, and coagulation problems due to the aqueous solution's diffusion and invasion into surrounding tissues.
Innovation Solution
A composition comprising Collagenase G and Collagenase H in a ratio of 1:2 to 1:4, preferably 1:3, formulated as a hyaluronic acid gel for controlled release, allowing sequential or simultaneous administration to enhance efficacy and reduce secondary effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a 1:1 ratio of Collagenase G and H is used in aqueous solution, then the treatment can be administered, but the enzyme activity is difficult to control and secondary effects like tendon rupture and allergic reactions occur
Solution Approach 1:
The patent changes the concentration ratio parameter from the conventional 1:1 to a range of 1:2 to 1:4 (preferably 1:3) of Collagenase G to Collagenase H. This parameter change optimizes the synergistic effect between the two enzymes, improving collagen hydrolysis efficiency while reducing secondary effects. The specific ratio optimization allows better control over enzyme activity and therapeutic outcome.
Solution Approach 2:
The patent formulates the collagenase mixture with hyaluronic acid to create a composite gel formulation. This composite material provides controlled release of the enzymes, improves stability, and reduces diffusion into surrounding tissues. The hyaluronic acid gel acts as a carrier matrix that modulates the release kinetics and enhances the therapeutic index of the collagenase treatment.
2Ease of operation
If aqueous solution is used for collagenase administration, then the enzymes can be delivered, but they diffuse into surrounding tissues causing tendon rupture and coagulation problems
Solution Approach 1:
The patent introduces hyaluronic acid gel as an intermediary carrier between the collagenase enzymes and the target tissue. This intermediary provides controlled release, preventing rapid diffusion into surrounding tissues while ensuring adequate enzyme delivery to the treatment site. The gel matrix modulates the release kinetics and reduces harmful effects on adjacent structures.
Solution Approach 2:
The patent changes the physical state parameter from aqueous solution to gel formulation. This parameter change significantly reduces the diffusion rate of the enzymes into surrounding tissues while maintaining delivery capability. The gel formulation provides sustained release and improves the safety profile by confining the enzymatic activity to the treatment area.
3Productivity
If higher doses of collagenase are administered to improve efficacy, then collagen hydrolysis is enhanced, but secondary effects increase
Solution Approach 1:
The patent optimizes the ratio parameter of Collagenase G to Collagenase H from 1:1 to 1:2 to 1:4, which enhances collagen hydrolysis efficiency through synergistic interaction. This ratio optimization allows achieving higher efficacy at lower total doses, thereby reducing secondary effects while maintaining or improving therapeutic outcome.
Solution Approach 2:
The patent uses hyaluronic acid gel as a composite carrier to provide controlled release of the collagenase mixture. This controlled release mechanism ensures sustained enzymatic activity at the treatment site, improving collagen hydrolysis efficacy over time while reducing peak concentrations that cause secondary effects. The gel matrix modulates the release kinetics to maintain therapeutic levels without excessive dosing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves higher collagen hydrolysis efficacy with reduced secondary effects, improved stability, and fewer administrations required, effectively treating collagen-related diseases like Dupuytren's contracture with enhanced specificity and safety.
Implementation Method 1
Collagenases are proteolytic enzymes that bind and cut specifically to sequences containing amino acids Pro-X-Gly-Pro
Implementation Method 2
collagenases are the only enzymes able to specifically recognize native collagen and hydrolyze it
Implementation Method 3
simultaneous utilization using a controlled release system based on a hyaluronic acid gel
Implementation Method 4
The aqueous solution once injected, could diffuse freely to adjacent areas
Data Source
AI summary
Compositions comprising collagenase G and collagenase H (in a ratio between 1:2.5 and 1:3.5), optionally formulated in hydrogels, and its uses as medicament for the treatment of diseases involving alterations of collagen, such as fibromatosis, palmar Dupuytren's contracture, La Peyronie's disease, Ledderhose's disease or retractable scars.